Download full report with analyst certification and important disclosures
Oct 31 2024, 07:30 GMT
dsm-firmenich
Q3 in-line, guidance raised to reflect temporary vitamin effects
- Sectors : Foods
- Companies : dsm-firmenich
DAVY VIEW
dsm-firmenich has delivered an in-line result for Q3 with EBITDA +32% year-on-year (yoy). As expected, FY guidance was raised to reflect recent dislocation in the vitamin market. We envisage limited change to consensus forecasts. Recent share price weakness looks overdone.
